miRoncol Health will launch the first-of-its-kind microRNA based mutli-cancer risk stratification blood test in 2026. The proof of concept studies demonstrated superior performance particularly for early stage cancers with ~90% sensitivity at 99%+ specificity among ~80% common solid tumors other than breast cancer. It outperforms mainstream ctDNA based tests and is also more affordable due to requiring only a few microRNAs and using widely available PCR technology.